Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04154189 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT04154189 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 81 participants.
The verdict
NCT04154189, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
This Is a Multicenter, Randomized, Open-Label, Parallel-Group, Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents, and Young Adults with Relapsed or Refractory Osteosarcoma.
Interventions
- DRUG Etoposide
- DRUG Ifosfamide
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2020-03-23 |
| Est. Completion | 2023-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04154189
The ClinicalTrials.gov registry entry for NCT04154189 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Etoposide is the first listed.
NCT04154189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04154189 about?
NCT04154189 is a clinical study titled "A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma". This Is a Multicenter, Randomized, Open-Label, Parallel-Group, Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents, and Young Adults with Relapsed or Refractory Osteosarcoma.
What is the current status of trial NCT04154189?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2020-03-23. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT04154189?
The interventions under investigation include: Etoposide (DRUG), Ifosfamide (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04154189?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.